ArticleJournal of neuro-oncology2026
Survival, late toxicity and ability to return to work after proton radiotherapy for low-grade gliomas.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLevel I evidence to inform decisions on radiation modality and chemotherapy regimen choice in adult-type diffuse gliomas CNS WHO grade 2 are awaited. The retrospective analysis was performed to assess overall survival (OS), progression-free survival (PFS) and late toxicity including ability to return to work in 2016 CNS WHO grade 1 and grade 2 gliomas (low-grade gliomas [LGG]) patients treated with intensity modulated proton beam radiotherapy (IMPT).
methodsPatients with 2016 CNS WHO LGG after surgery, treated with IMPT at our institution from 2016 to 2021 were eligible for this analysis. Data were retrospectively collected from medical and imaging records.
results143 patients were identified. Diffuse astrocytoma isocitrate dehydrogenase (IDH) mutant was the predominant phenotype. Median follow-up was 66.5 months. Five-year OS and PFS were 78.21%, 76.52%, 85.92% and 80.34%, 65.59%, 86.07% for the whole cohort, diffuse astrocytoma IDH mutant and gemistocytic astrocytoma combined, and oligodendroglioma IDH mutant 1p19q codeleted respectively. Mean residual tumor volume was 61.3 cm³ and mean planning target volume (PTV) was 335.7 cm³. At 12, 36 and 60 months after IMPT 61 (42.66%), 61 (42.66%) and 59 (41.26%) patients held down in full-time employment. Each additional cubic centimeter of PTV significantly reduced ability to return to the initial full-time work by 0.5% (Odds Ratio [OR] = 0.995, p = 0.046). 4 cases of CTCAE grade 3 late toxicity were reported (2 cases of optic neuropathy, 1 late fatigue, and 1 muscle weakness).
conclusionsIrradiation brain volume is associated with maintaining ability to work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.